How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Perini, Guilherme Fleury; Fischer, Thaís; Gaiolla, Rafael Dezen; Rocha, Talita Bueno; Bellesso, Marcelo; Teixeira, Larissa Lane Cardoso; Delamain, Márcia Torresan; Scheliga, Adriana Alves de Souza; Ribeiro, Gustavo Meirelles; Neto, Jorge Megid; Baiocchi, Otavio C. G.; Abdo, André; Arrais‐Rodrigues, Celso; Fogliatto, Laura; Bigni, Ricardo; Schaffel, Rony; Biasoli, Irène; Pereira, Juliana; Nabhan, Samir Kanaan; Souza, Cármino Antonio De; Chiattone, Carlos S.

doi:10.1016/j.htct.2020.04.002

Cited by 35 publications

(69 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A Brazilian task force commented on the management of lymphoid malignancies during the COVID-19 outbreak [19]. A recommendation regarding modifications of the use of radiotherapy was given for early-stage Hodgkin's lymphoma.…”

Section: Lymphomamentioning

confidence: 99%

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Vordermark

2020

Radiat Oncol

View full text Add to dashboard Cite

To examine, if a shift in indications for radiotherapy is to be expected in the context of the COVID-19 pandemic, the database Pubmed was searched for multidisciplinary or surgical expert recommendations on the role of radiotherapy in modified treatment concepts. Increased use of radiotherapy or chemoradiation instead of surgical treatment was recommended for defined patient groups with head-and-neck cancer, lung cancer, cervix cancer, esophageal cancer and prostate cancer. Omission of radiotherapy was considered in elderly patients with low-risk breast cancer and in early-stage Hodgkin's lymphoma. Only adjustments to the timing of radiotherapy were discussed for sarcoma and rectal cancer. Emerging recommendations on multidisciplinary cancer treatment concepts during the COVID-19 pandemic indicate a shift in radiotherapy indications and a potentially increased demand for radiotherapy.

show abstract

Section: Lymphomamentioning

confidence: 99%

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Vordermark

2020

Radiat Oncol

View full text Add to dashboard Cite

show abstract

“…R‐CHOP continues to be the standard of care for young DLBCL patients, while R‐mini‐CHOP with growth factor support is the recommended strategy for older and unfit patients. Avoidance of intensified regimens during COVID‐19 outbreak, such as DA‐EPOCH‐R, usually administered in HGBL, has been recommended in recent guidelines 1,2 in order to reduce immunosuppression and potential complications. In contrast, our centre decided to keep these regimens, giving priority to reaching the best disease control and outcome.…”

Section: Discussionmentioning

confidence: 99%

“…At the beginning, few guidelines regarding the management of lymphoid malignancies during COVID‐19 pandemic were available 1,2 . As treatment of patients with diffuse large B cell lymphoma (DLBCL) and high‐grade B cell lymphoma (HGBL) cannot be delayed without detrimental effects on the outcomes, we had to adapt our clinical practices to cope with these concerns.…”

mentioning

confidence: 99%

Managing the front‐line treatment for diffuse large B cell lymphoma and high‐grade B cell lymphoma during the COVID‐19 outbreak

et al. 2020

View full text Add to dashboard Cite

Summary The COVID‐19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment who represent a vulnerable population for SARS‐CoV‐2 infection. Aggressive lymphoid neoplasms, such as diffuse large B cell lymphoma and high‐grade B cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed to minimise the risk of SARS‐CoV‐2 infection while continuing haematological treatment. In this report, we analyse the management of front‐line therapy in 18 patients during the COVID‐19 outbreak, as well as the results of the implemented measures in their outcome.

show abstract

“…Despite the paucity of current available data, several medical societies have provided clinical practice guidelines for management of patients with hematologic malignancies in order to optimize therapy and limit infection risk and complications (9,51). Consensus recommendations have been based on extrapolated information from other coronavirus epidemics and expert opinions based on educated assumptions.…”

Section: Published Guidelines For Covid-19 Screeningmentioning

confidence: 99%

“…As a result, despite the limited available data, the oncology community has been pro-actively engaged in issuing guidelines to help clinical practice with the goal of decreasing exposure and complication risks from COVID-19 among patients with cancer. For instance, recommendations have emerged to consider on a case-by-case basis, whenever possible, options of delaying/dose reducing treatment, using lower-intensity therapy, postponing unnecessary radiological evaluations, and prioritizing telemedicine ( 5 – 9 ).…”

Section: Introductionmentioning

confidence: 99%

Screening Strategies for COVID-19 in Patients With Hematologic Malignancies

et al. 2020

View full text Add to dashboard Cite

COVID-19 has been declared a pandemic by the world health organization. Patients with cancer, and particularly hematologic malignancies may be at higher risk for severe complications due to their malignancy, immune dysregulation, therapy, and associated comorbidities. The oncology community has been proactive in issuing practice guidelines to help optimize management, and limit infection risk and complications from SARS-COV-2. Although hematologic malignancies account for only 10% of all cancers, their management is particularly complex, especially in the time of COVID-19. Screening or early detection of COVID-19 are central for preventative/mitigation strategy, which is the best current strategy in our battle against COVID-19. Herein, we provide an overview of COVID-19 screening strategies and highlight the unique aspects of treating patients with hematologic malignancies.

show abstract

How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation

Abstract: HTCT 3120 1-8 hematol transfus cell ther. 2 0 2 0;x x x(x x):xxx-xxx w w w . h t c t . c o m . b r Hematology, Transfusion and Cell Therapy

Cited by 35 publications

References 61 publications

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups

Managing the front‐line treatment for diffuse large B cell lymphoma and high‐grade B cell lymphoma during the COVID‐19 outbreak

Screening Strategies for COVID-19 in Patients With Hematologic Malignancies

Contact Info

Product

Resources

About